Rivalry Intensifies In Europe For Biotech Funding, Product Development
This article was originally published in The Pink Sheet Daily
U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.
You may also be interested in...
European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box
EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.
The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.